NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware. Show more
Location: 1201 Orange Street, Wilmington, DE, 19801, United States | Website: https://www.nrxpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
61.8M
52 Wk Range
$1.10 - $6.01
Previous Close
$2.60
Open
$2.66
Volume
191,298
Day Range
$2.53 - $2.66
Enterprise Value
68.65M
Cash
2.91M
Avg Qtr Burn
-2.978M
Insider Ownership
11.55%
Institutional Own.
25.47%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NRX-101 Details Treatment Resistant Depression, Bipolar depression | NDA Submission | |
NRX-100 (preservative-free IV ketamine) Details Suicidal Depression | NDA Submission | |
NRX-101 Details Chronic pain | Phase 2 Data readout | |
NRX-101 Details Post-traumatic stress disorder (PTSD) | Phase 2 Initiation | |
HTX-100 (IV ketamine) Details Acute Suicidal Ideation and Behavior, Bipolar depression | Phase 1 Update | |
BRILIFE Details COVID-19 | Failed Discontinued | |
Failed Discontinued |